Washington (July 12, 2002) -- The Securities and Exchange Commission is investigating pharmaceutical concern Bristol-Myers Squibb Co. for allegedly inflating its revenue.

A company representative confirmed that the regulator was conducting an investigation but declined to elaborate. However, a report by the Financial Times stated that Bristol-Myers allegedly inflated sales by roughly $1 billion in an effort to meet earnings targets. Regulators are examining whether Bristol-Myers had given its wholesalers incentives to purchase over-allotments of the company’s prescription drugs.

Register or login for access to this item and much more

All Accounting Today content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access